Sort   by:  
 Page size 
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
ProteomicsCodon Specific Readthrough as a Mechanism of BRCA2 Restoration in Acquired PARP Inhibitor and Chemotherapy Resistance
Alteration of the gene encoding BRCA2, a protein involved in homologous recombination (HR), by missense or nonsense mutations results in sensitivity of a subset of breast and ovarian cancers to platinating agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Conversely, resistance to these agen...
ORGANISM(S): Homo sapiens (Human) 
2025-10-27 | PXD037989 | Pride
Translational readthrough Ovarian cancer Brca2 
TranscriptomicsUp-regulation of IFN-related genes in BRCA2-/- cells
Microarray-based expression profiling of BRCA2 knockout and isogenic wild type HCT116 human colorectal cancer cells One way ANOVA, single factor comparison of wild type and BRCA2 knockout cells, three CEL files for wild type, three CEL files for BRCA2 knockout
ORGANISM(S): Homo sapiens 
2014-07-01 | E-GEOD-54830 | biostudies-arrayexpress
ProteomicsSILAC proteomics analysis to assess differences in protein expression upon BRCA2 inactivation
BRCA2 maintains genome stability by facilitating DNA repair via homologous recombination and replication fork stability. Loss of BRCA2 is deleterious for survival of normal cells, but is paradoxically tolerated in cancer cells. Using quantitative mass-spectrometry, differences in protein expression ...
ORGANISM(S): Homo sapiens (Human) 
2018-12-19 | PXD007253 | Pride
Silac breast cancer brca2 hcc38 
TranscriptomicsCGH profiles of primary breast carcinomas from HBOC (Hereditary Breast and Ovarian Cancer) families
89 tumors from women that were eligible for, and subjected to, routine diagnostic testing according to the HBOC criteria but were negative for pathogenic BRCA1/2-mutations or carried an UV in either BRCA1/2 A BRCA2-classifier was built using array-CGH profiles of 28 BRCA2-mutated and 28 sporadic bre...
ORGANISM(S): Homo sapiens 
2010-07-05 | E-GEOD-22481 | biostudies-arrayexpress
TranscriptomicsClassifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
Pathogenic germline mutations in BRCA1 or BRCA2 are detected in less than one third of families with a strong history of breast cancer. It is therefore expected that mutations still remain undetected by currently used screening methods. In addition, a growing number of BRCA1/2 sequence variants of u...
ORGANISM(S): Homo sapiens 
2013-06-28 | E-GEOD-40115 | biostudies-arrayexpress
TranscriptomicsDetermination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling
Approximately 5% of all breast cancers can be attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2. We searched for genes that have the potential to distinguish healthy BRCA1 and BRCA2 mutation carriers from non-carriers based on differences in expression pr...
ORGANISM(S): Homo sapiens 
2013-01-10 | E-GEOD-39976 | biostudies-arrayexpress
ProteomicsIdentification of BRCA2-DSS1 new partner HELZ
R-loops are dynamic three-stranded nucleic acid structures that regulate genome function but can threaten genome stability if not properly resolved. BRCA2, a key player in homologous recombination (HR), also regulates R-loops, though the mechanisms remain unclear. To uncover novel R-loop regulators,...
ORGANISM(S): Homo sapiens (Human) 
2025-12-30 | PXD066766 | Pride
Hela Biotinid-dss1 Brca2 Helz 
GenomicsCPCG BRCA2 - samples
Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations
EGAD00001002739 | EGA
GenomicsMED12L Gene Alterations Define Aggressive BRCA2-Mutant Prostate Cancers
Germline mutation of BRCA2 increases the lifetime risk of developing prostate cancer (PCa) by over 700%. BRCA2-mutant PCa have poorer prognosis than sporadic PCa, with rapid development of metastatic, castrate-resistant prostate cancer (mCRPC) and 5-year cancer-specific survival rates of ~50-60%1-4....
EGAS00001001615 | EGA
Sort   by:  
 Page size